JP2018517892A - 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル - Google Patents

結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル Download PDF

Info

Publication number
JP2018517892A
JP2018517892A JP2017552968A JP2017552968A JP2018517892A JP 2018517892 A JP2018517892 A JP 2018517892A JP 2017552968 A JP2017552968 A JP 2017552968A JP 2017552968 A JP2017552968 A JP 2017552968A JP 2018517892 A JP2018517892 A JP 2018517892A
Authority
JP
Japan
Prior art keywords
panel
proteins
individual
biomarker
catd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017552968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517892A5 (enExample
Inventor
ブルーム，ジョン
ジョーンズ，ジェフリー
ベンズ，ライアン
カオ，アティット
クロナー，リサ
ディロン，ロスリン
ヨウ，ジア
ウィルコックス，ブルース
Original Assignee
アプライド プロテオミクス，インク．
アプライド プロテオミクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプライド プロテオミクス，インク．, アプライド プロテオミクス，インク． filed Critical アプライド プロテオミクス，インク．
Publication of JP2018517892A publication Critical patent/JP2018517892A/ja
Publication of JP2018517892A5 publication Critical patent/JP2018517892A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
JP2017552968A 2015-04-10 2016-04-08 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル Pending JP2018517892A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562146158P 2015-04-10 2015-04-10
US62/146,158 2015-04-10
US201562160560P 2015-05-12 2015-05-12
US62/160,560 2015-05-12
US201562165846P 2015-05-22 2015-05-22
US62/165,846 2015-05-22
US201562196889P 2015-07-24 2015-07-24
US62/196,889 2015-07-24
US201562239771P 2015-10-09 2015-10-09
US62/239,771 2015-10-09
PCT/US2016/026773 WO2016164815A1 (en) 2015-04-10 2016-04-08 Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Publications (2)

Publication Number Publication Date
JP2018517892A true JP2018517892A (ja) 2018-07-05
JP2018517892A5 JP2018517892A5 (enExample) 2019-05-16

Family

ID=55795201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017552968A Pending JP2018517892A (ja) 2015-04-10 2016-04-08 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル

Country Status (7)

Country Link
US (3) US9689874B2 (enExample)
EP (1) EP3281016A1 (enExample)
JP (1) JP2018517892A (enExample)
CA (1) CA2982169A1 (enExample)
GB (1) GB2545361B (enExample)
HK (1) HK1255533A1 (enExample)
WO (1) WO2016164815A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
KR101937531B1 (ko) * 2016-09-28 2019-01-10 국립암센터 대장암 진단 장치와 대장암 진단 정보 제공 방법
US20180100858A1 (en) 2016-10-07 2018-04-12 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
US11062792B2 (en) 2017-07-18 2021-07-13 Analytics For Life Inc. Discovering genomes to use in machine learning techniques
US11139048B2 (en) 2017-07-18 2021-10-05 Analytics For Life Inc. Discovering novel features to use in machine learning techniques, such as machine learning techniques for diagnosing medical conditions
CN111684282A (zh) * 2017-12-05 2020-09-18 迪森德克斯公司 结直肠癌生物标志物的稳健小组
JP7102509B2 (ja) * 2018-04-04 2022-07-19 富士フイルム株式会社 医療文書作成支援装置、医療文書作成支援方法、及び医療文書作成支援プログラム
CN112970067A (zh) * 2018-06-30 2021-06-15 20/20基因系统股份有限公司 癌症分类器模型、机器学习系统和使用方法
AU2019297457A1 (en) * 2018-07-05 2021-02-25 Edp Biotech Corporation Kits and methods for detecting markers
US11011276B2 (en) * 2018-07-09 2021-05-18 Chang Gung Memorial Hospital, Linkou Method for establishing computer-aided data interpretation model for immune diseases by immunomarkers and visualization
JP2022550940A (ja) * 2019-10-01 2022-12-06 エーシー イミューン ソシエテ アノニム リガンドのスクリーニング用のマイクロ放射性結合アッセイ
US20210349017A1 (en) * 2020-05-08 2021-11-11 Caci, Inc. - Federal Systems and methods for detection of biological agents using infrared spectroscopy
CN116868229A (zh) * 2021-02-16 2023-10-10 威里利生命科学有限责任公司 用于数字化病理学样本中的生物标志物检测的系统和方法
WO2022241264A2 (en) * 2021-05-13 2022-11-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis
WO2024208824A1 (en) * 2023-04-03 2024-10-10 Oncodiag Methods for the diagnosis and surveillance of cancer
CN118983105A (zh) * 2024-06-24 2024-11-19 浙江省肿瘤医院 一种用于高级别浆液性卵巢癌晚期患者无复发生存的预测模型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506917A (ja) * 2007-12-10 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 結腸直腸癌のためのマーカーパネル
JP2013511728A (ja) * 2009-11-20 2013-04-04 ユニバーシティ オブ ルイスビル リサーチ ファンデーション，インコーポレイテッド 癌のバイオマーカー
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4517289A (en) 1982-08-18 1985-05-14 Brigham And Women's Hospital Monoclonal antibodies for human tissue cross-matching
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5790761A (en) 1992-12-11 1998-08-04 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
AU6350894A (en) 1993-03-05 1994-09-26 Clifford W. Schweinfest Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
US7229770B1 (en) 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US5800347A (en) 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
NO954667D0 (no) 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
US5983211A (en) 1996-01-24 1999-11-09 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6303372B1 (en) 1998-06-12 2001-10-16 Chiron Corporation cDNA molecule encoding human CIF130
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
CA2372667A1 (en) 1999-01-10 2000-11-23 Steven Laken Methods of detecting colorectal disease by conduction an assay to detect a mutation in a bat-26 locus
US7153700B1 (en) 1999-03-26 2006-12-26 Dana-Farber Cancer Institute, Inc. Methods and compositions for diagnosing and predicting the behavior of cancer
DE60021068T2 (de) 1999-04-09 2006-05-18 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
US20010041365A1 (en) 2000-01-10 2001-11-15 Michael Laposata Methods for monitoring alcohol consumption
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
US7577683B2 (en) 2000-06-08 2009-08-18 Ingenuity Systems, Inc. Methods for the construction and maintenance of a knowledge representation system
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
AU2001280639A1 (en) 2000-07-18 2002-01-30 Millennium Pharmaceuticals, Inc. 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
US6706506B2 (en) 2000-07-24 2004-03-16 Cornell Research Foundation, Inc. Detection of epithelial cell cancers and precancerous conditions
AU2001297575A1 (en) 2000-11-08 2002-10-08 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
JP2005518779A (ja) 2001-03-23 2005-06-30 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ガンを発症する危険性を明らかにするための方法およびキット、ガン治療の有効性および投与量を評価するための方法およびキット、ならびにｄｎａ修復酵素の活性とガンとを相関させるための方法およびキット
US20030064385A1 (en) 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
US7031846B2 (en) 2001-08-16 2006-04-18 Affymetrix, Inc. Method, system, and computer software for the presentation and storage of analysis results
EP1430071B1 (en) 2001-09-07 2011-04-06 The Johns Hopkins University School Of Medicine Secreted and cell surface genes expressed in benign and malignant colorectal tumors
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
US20030186248A1 (en) 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
WO2003097872A2 (en) 2002-05-21 2003-11-27 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
US20050153382A1 (en) 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
DE602004009716T2 (de) 2004-08-13 2008-08-28 Indivumed Gmbh Verwendung von transthyretin als biomarker zum nachweis von kolorektalen adenomen; verfahren und nachweis-system
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
WO2006047481A2 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
WO2006094149A2 (en) 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
US9075062B2 (en) 2005-03-22 2015-07-07 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Identification of biomarkers by serum protein profiling
EP1920071B1 (en) 2005-07-29 2018-12-26 Siemens Healthcare Diagnostics Inc. Neoplastic disease-related methods, kits, systems and databases
CA2772688A1 (en) 2005-09-12 2007-03-22 Phenomenome Discoveries Inc. Methods for the diagnosis of colorectal cancer and ovarian cancer health states
CN101263391A (zh) 2005-09-12 2008-09-10 菲诺梅诺米发现公司 通过测量维生素e-相关的代谢物诊断结肠直肠癌和卵巢癌的方法
US7892758B2 (en) 2005-09-27 2011-02-22 University Of Saskatchewan Use of N-myristoyltransferase on non-tumor tissue for cancer diagnosis
EP2177910A1 (en) 2005-11-10 2010-04-21 Aurelium Biopharma Inc. Tissue diagnostics for breast cancer
GB0524190D0 (en) 2005-11-28 2006-01-04 Helse Stavanger Hf Method
ES2277785B1 (es) 2005-12-21 2008-06-16 Oryzon Genomics, S.A. Metodo de analisis de expresion diferencial en cancer colorectal.
US20090035801A1 (en) 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
KR20090003178A (ko) 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
US20070231304A1 (en) 2006-01-30 2007-10-04 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
WO2007127002A2 (en) 2006-03-31 2007-11-08 Cell Signaling Technology, Inc. Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
CA2657691A1 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008073858A2 (en) 2006-12-08 2008-06-19 The Johns Hopkins University Cancer chemoprevention strategy based on loss of imprinting of igf2
ATE535805T1 (de) 2007-01-26 2011-12-15 Univ Louisville Res Found Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2008116178A2 (en) 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
CN101971033A (zh) 2007-06-04 2011-02-09 戴诺普雷克斯公司 用于结直肠癌的生物标志物组合
WO2009015299A1 (en) 2007-07-26 2009-01-29 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
DE102007034993A1 (de) 2007-07-26 2009-01-29 Hanna Diehl Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs
US8426140B2 (en) 2007-09-28 2013-04-23 Royal College Of Surgeons In Ireland Method of assessing colorectal cancer status in an individual
ATE521894T1 (de) 2007-11-20 2011-09-15 Hoffmann La Roche Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
KR101058753B1 (ko) 2007-11-22 2011-08-24 한국생명공학연구원 대장암 마커로서의 ｅｓｍ－１ 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도
BRPI0820793A2 (pt) 2007-12-10 2015-06-16 Hoffmann La Roche Seprase como marcador de câncer
US20110053879A1 (en) 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
CN102027128A (zh) 2008-02-11 2011-04-20 哈达斯特医学服务与开发有限公司 作为癌症标志物的结肠癌相关的转录物1(ccat-1)
US20110076700A1 (en) 2008-02-29 2011-03-31 Nihon University Anti-crp antibody and utilization of the same
US20110245087A1 (en) 2008-03-18 2011-10-06 Gunter Weiss Method for optimizing and validating an assay for determining the presence or absence of a medical condition
US20110104256A1 (en) 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
SG189774A1 (en) 2008-04-10 2013-05-31 Genenews Corp Method and apparatus for determining a probability of colorectal cancer in a subject
CN102027373B (zh) 2008-05-14 2017-10-10 埃斯苏黎世公司 发现用于前列腺癌诊断和治疗之生物标志物和药物靶标的方法及其确立的生物标志物测定
ES2506116T3 (es) 2008-05-23 2014-10-13 Biocartis Nv Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
MX2011000655A (es) 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
EP2169077A1 (en) 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
US20100204299A1 (en) 2009-02-11 2010-08-12 Daniel Regnier C-cbl and antagonists thereof for the treatment and diagnosis of cancer
EP2398918B1 (en) 2009-02-20 2018-06-20 Onconome, Inc. Methods for diagnosis and prognosis of colorectal cancer
CN102326081B (zh) 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
CA2777800C (en) 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2011119934A2 (en) 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
US10119959B2 (en) 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
GB201012590D0 (en) 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
US8389684B2 (en) 2010-09-13 2013-03-05 Tsinghua University Tumor biomarker
WO2012101283A1 (en) 2011-01-28 2012-08-02 Biosystems International Sas Combinatorial biomarkers for clinical applications in lung cancer patient management
CA2827894A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CA2845568A1 (en) 2011-08-19 2013-02-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
ES2762403T3 (es) 2012-04-26 2020-05-25 Stichting Vumc Biomarcadores

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506917A (ja) * 2007-12-10 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 結腸直腸癌のためのマーカーパネル
JP2013511728A (ja) * 2009-11-20 2013-04-04 ユニバーシティ オブ ルイスビル リサーチ ファンデーション，インコーポレイテッド 癌のバイオマーカー
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
COUTSOFTIDES ET AL: "Colonoscopy and the Management of Polyps Containing Invasive Carcinoma", ANN SURG, vol. 188, no. 5, JPN6020002747, 1978, pages 638 - 641, ISSN: 0004201082 *
ETZIONI ET AL: "THE CASE FOR EARLYDETECTION", NATURE REVIEWS, vol. 3, JPN6020002742, 2003, pages 1 - 10, ISSN: 0004201080 *
FERRONI ET AL: "PROGNOSTIC VALUE SOLUBLE P-SELECTIN LEVELS IN COLORECTAL CANCER", INT J CANCER, vol. 111, JPN6020002734, 2004, pages 404 - 408, ISSN: 0004201076 *
KOPETZ ET AL: "Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Can", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 2, JPN6020002755, 2010, pages 453 - 459, ISSN: 0004201085 *
LEE ET AL: "Macrophage Migration Inhibitory Factor May Be Used as an Early Diagnostic Marker in Colorectal Carci", AM J CLIN PATHOL, vol. 129, JPN6020002735, 2008, pages 772 - 779, ISSN: 0004201077 *
MERCER: "Use of Multiple Markers to Enhance Clinical Utility", IMMUNOL SER, vol. 53, JPN6020002745, 1990, pages 39 - 54, ISSN: 0004201081 *
MINICOZZI ET AL: "Disease presentation, treatment and survival for Italian colorectal cancer patients: a EUROCARE high", EUR J PUBLIC HEALTH, vol. 24, no. 1, JPN6020002749, 2014, pages 98 - 100, ISSN: 0004201083 *
PINCZOWER ET AL: "CHARACTERISATION OF THE TUMOUR-ASSOCIATED CARBOHYDRATE EPITOPE RECOGNISED BY MONOCLONAL ANTIBODY 4D3", INT J CANCER, vol. 66, JPN6020002739, 1996, pages 636 - 644, ISSN: 0004201079 *
PINCZOWER: "NOMOCLONAL ANTIBODY 4D3 DETECTS SMALL INTESTINAL MUCIN ANTIGEN (SIMA)-GLYCOPROTEIN IN THE SERUM OF P", INT J CANCER, vol. 54, JPN6020002737, 1993, pages 391 - 396, ISSN: 0004201078 *
THORSEN ET AL: "Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplas", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 11, no. 253, JPN6020002752, 2013, pages 1 - 13, ISSN: 0004201084 *
WILD ET AL: "A Combination of Serum Markers for the Early Detection of Colorectal Cancer", CLIN CANCER RES, vol. 16, no. 24, JPN6020002731, 2010, pages 6111 - 6121, ISSN: 0004201074 *
XIE ET AL: "Novel Proteomic Strategy Reveal Combined α1 Antitrypsin and Cathepsin D as Biomarkers for Colorecta", JOURNAL OF PROTEOME RESEARCH, vol. 9, JPN6020002733, 2010, pages 4701 - 4709, ISSN: 0004201075 *

Also Published As

Publication number Publication date
CA2982169A1 (en) 2016-10-13
GB201703773D0 (en) 2017-04-26
US20160299144A1 (en) 2016-10-13
WO2016164815A1 (en) 2016-10-13
GB2545361A (en) 2017-06-14
GB2545361B (en) 2018-01-24
US20190257835A1 (en) 2019-08-22
EP3281016A1 (en) 2018-02-14
US20170370937A1 (en) 2017-12-28
HK1255533A1 (zh) 2019-08-16
US9689874B2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
US9689874B2 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CN104969071B (zh) 用于评估结肠肿瘤的存在或风险的方法
Wadsworth et al. Identification of patients with head and neck cancer using serum protein profiles
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20170176441A1 (en) Protein biomarker profiles for detecting colorectal tumors
HK1248316A1 (en) Methods of assessing colorectal health of an individual
JP7311417B2 (ja) 肺癌の検出および処置のための方法
JP2017530356A (ja) 心血管系のリスクイベントの予測及びその使用
CN117396983A (zh) 多组学评估
KR20240004546A (ko) 결장직장암에 대한 바이오마커
WO2025145100A1 (en) Multi-omics assessment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210322